Citations (5)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
José María Serra López-Matencio, Ana Beatriz Gago-Veiga, Manuel Gómez, Estefanía Alañón Plaza, Gina Paola Mejía, Miguel Ángel González-Gay & Santos Castañeda. (2022) Treatment of migraine with monoclonal antibodies. Expert Opinion on Biological Therapy 22:6, pages 707-716.
Read now
Read now
Articles from other publishers (4)
Dawn C. Buse, Lynda J. Krasenbaum, Michael J. Seminerio, Elizabeth R. Packnett, Karen Carr, Mario Ortega & Maurice T. Driessen. (2024) Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response. Pain and Therapy 13:3, pages 511-532.
Crossref
Crossref
Leon S. Moskatel & Niushen Zhang. (2023) The Role of Step Therapy in the Treatment of Migraine. Current Pain and Headache Reports 27:10, pages 571-577.
Crossref
Crossref
Jie Zhang, Siyu Wu, Yingjie Wen, Duo Lai, Shizi Kuang, Ruonan Zhang, Xiaoxia Xu, Fengliang Jin, Hanhong Xu, Xiao-Qiang Yu & Xuehua Shao. (2023)
Eurycomanone (EN) Activates Transcription Factor FoxO by Inhibiting the Insulin Signaling Pathway to Suppress the Development of
Spodoptera frugiperda
. Journal of Agricultural and Food Chemistry 71:27, pages 10314-10325.
Crossref
Crossref
Fidel Dominique Festin Ambat, Enrico Bentivegna & Paolo Martelletti. (2022) Novel Migraine Therapies May Reduce Public and Personal Disadvantages for People with Migraine. BioDrugs 36:3, pages 337-339.
Crossref
Crossref